CD160: a unique activating NK cell receptor.

Here we discuss CD160 an essential NK cell activating receptor that remains poorly understood. CD160 receptor exhibits a number of unique structural and functional characteristics that are not common to other killer immunoglobulin-like receptors that recognize major histocompatibility complex (MHC) class I molecules: (1) In addition to humans and mice, the cd160 gene is conserved in several other mammal species; (2) cd160 is located outside the NK gene complex and the Leukocyte Receptor Complex in humans; (3) CD160 expression is associated to the CD56(dim) CD16+ cytotoxic NK cell phenotype; (4) both human and mouse CD160 recognize MHC class Ia and Ib molecules; (5) unlike the other MHC class I-dependent activating NK receptors, CD160 is a glycosylphosphatidylinositol-anchored molecule with a single immunoglobulin-like domain, and does not bear immunoreceptor tyrosine-based activation motifs. Consequently, CD160 cannot signal by itself, requiring the recruitment of adaptor proteins. CD160 recruits phosphoinositide-3 kinase to trigger cytotoxicity and cytokine secretion; (6) specific engagement of NK CD160 receptor expressed by circulating NK cells produces proinflammatory cytokines IFN-γ, TNF-α, and, most notably, IL-6 and IL-8 as well as MIP1-β chemokine. The level of CD160-mediated IFN-γ production is always higher than the one observed after engagement of the CD16 receptor.

[1]  G. Freeman,et al.  Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. , 1998, Journal of immunology.

[2]  K. Liao,et al.  CD5‐low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells , 2008, Journal of leukocyte biology.

[3]  N. Stanietsky,et al.  Paired NK cell receptors controlling NK cytotoxicity , 2010, FEBS letters.

[4]  J. Dausset,et al.  BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Berrebi,et al.  Human decidual NK cells: unique phenotype and functional properties -- a review. , 2006, Placenta.

[6]  A. Bensussan,et al.  A Soluble Form of the MHC Class I-Specific CD160 Receptor Is Released from Human Activated NK Lymphocytes and Inhibits Cell-Mediated Cytotoxicity1 , 2007, The Journal of Immunology.

[7]  A. Bensussan,et al.  Identification and Characterization of a Transmembrane Isoform of CD160 (CD160-TM), a Unique Activating Receptor Selectively Expressed upon Human NK Cell Activation1 , 2009, The Journal of Immunology.

[8]  G. Leca,et al.  A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity , 1993, The Journal of experimental medicine.

[9]  A. Berrebi,et al.  Erratum to “Human Decidual NK Cells: Unique Phenotype and Functional Properties – A Review” [Placenta 27, supplement A, Trophoblast Research, Vol. 20: S34–S39] , 2006 .

[10]  A. Berrebi,et al.  Critical and Differential Roles of NKp46- and NKp30-Activating Receptors Expressed by Uterine NK Cells in Early Pregnancy1 , 2008, The Journal of Immunology.

[11]  K. Campbell,et al.  Signal transduction in natural killer cells. , 2006, Current topics in microbiology and immunology.

[12]  P. Bouteiller,et al.  Killers become builders during pregnancy , 2006, Nature Medicine.

[13]  S. Valitutti,et al.  CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment. , 2007, International immunology.

[14]  P. Le Bouteiller,et al.  Cutting Edge: Engagement of CD160 by its HLA-C Physiological Ligand Triggers a Unique Cytokine Profile Secretion in the Cytotoxic Peripheral Blood NK Cell Subset1 , 2004, The Journal of Immunology.

[15]  T. Yamamura,et al.  Murine CD160, Ig-Like Receptor on NK Cells and NKT Cells, Recognizes Classical and Nonclassical MHC Class I and Regulates NK Cell Activation1 , 2005, The Journal of Immunology.

[16]  G. Freeman,et al.  The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T‐cell activation , 2009, Immunological reviews.

[17]  M. Bagot,et al.  Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation. , 2007, The Journal of investigative dermatology.

[18]  F. Mami-Chouaib,et al.  Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Eric O Long,et al.  Activation, coactivation, and costimulation of resting human natural killer cells , 2006, Immunological reviews.

[20]  Judith E. Cartwright,et al.  Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. , 2006, Blood.

[21]  M. Nikolova,et al.  BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression. , 2002, International immunology.

[22]  J. Gribben,et al.  CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. , 2010, Blood.

[23]  G. Cai,et al.  Corrigendum: CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator , 2008, Nature Immunology.

[24]  Y. Obata,et al.  Characterization of murine CD160+ CD8+ T lymphocytes. , 2006, Immunology letters.

[25]  G. Freeman,et al.  Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. , 1999, Journal of immunology.

[26]  Lewis L Lanier,et al.  Up on the tightrope: natural killer cell activation and inhibition , 2008, Nature Immunology.

[27]  Eric Vivier,et al.  Functions of natural killer cells , 2008, Nature Immunology.